Msd Merck Co Drug Patent Portfolio
Msd Merck Co owns 4 orange book drugs protected by 6 US patents Given below is the list of Msd Merck Co's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10603282 | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine | 29 Nov, 2036 | Active |
| US10842751 | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine | 29 Nov, 2036 | Active |
| US8487093 | β-lactamase inhibitors | 21 Mar, 2033 | Active |
| US8486975 | Non-nucleoside reverse transcriptase inhibitors | 07 Oct, 2031 | Active |
| US8258132 | Pharmaceutical composition of a tachykinin receptor antagonist | 26 Sep, 2027 | Active |
| US6096742 | Polymorphic form of a tachykinin receptor antagonist | 01 Jul, 2018 | Expired |
Latest Legal Activities on Msd Merck Co's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Msd Merck Co.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Apr, 2024 | US10842751 |
| Notice of Final Determination -Eligible | 14 Mar, 2024 | US8486975 |
| Notice of Final Determination -Eligible | 14 Mar, 2024 | US8486975 |
|
FDA Final Eligibility Letter
Critical
| 07 Mar, 2024 | US8486975 |
|
FDA Final Eligibility Letter
Critical
| 07 Mar, 2024 | US8486975 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 16 Feb, 2024 | US8486975 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 16 Feb, 2024 | US8486975 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2024 | US8258132 |
| Requirement for information sent under 37 CFR 1.750 | 22 Jan, 2024 | US8486975 |
| Requirement for information sent under 37 CFR 1.750 | 22 Jan, 2024 | US8486975 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Aug, 2023 | US10603282 |
| transaction for FDA Determination of Regulatory Review Period | 04 Aug, 2023 | US8486975 |
| transaction for FDA Determination of Regulatory Review Period | 04 Aug, 2023 | US8486975 |
| transaction for FDA Determination of Regulatory Review Period | 14 Jul, 2023 | US8486975 |
| transaction for FDA Determination of Regulatory Review Period | 14 Jul, 2023 | US8486975 |
Msd Merck Co Drug Patents' Oppositions Filed in EPO
Msd Merck Co drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 06, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP02796109A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP02796109A | Apr, 2009 | Hexal AG | Patent maintained as amended |
| EP02796109A | Apr, 2009 | Teva Pharmaceutical Industries Ltd. | Patent maintained as amended |
Msd Merck Co's Family Patents
Msd Merck Co Drug List
Given below is the complete list of Msd Merck Co's drugs and the patents protecting them.
1. Delstrigo
Delstrigo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10603282 | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
29 Nov, 2036
(12 years from now)
| Active |
| US10842751 | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
29 Nov, 2036
(12 years from now)
| Active |
| US8486975 | Non-nucleoside reverse transcriptase inhibitors |
07 Oct, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Delstrigo's drug page
2. Emend
Emend is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8258132 | Pharmaceutical composition of a tachykinin receptor antagonist |
26 Sep, 2027
(2 years from now)
| Active |
| US6096742 | Polymorphic form of a tachykinin receptor antagonist |
01 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emend's drug page
3. Pifeltro
Pifeltro is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8486975 | Non-nucleoside reverse transcriptase inhibitors |
07 Oct, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pifeltro's drug page
4. Recarbrio
Recarbrio is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8487093 | β-lactamase inhibitors |
21 Mar, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Recarbrio's drug page